Search Results
Jul 30, 2026, 09:00 ET Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jul 30, 2026, 07:00 ET Basking Biosciences Announces Publication Showing BB-031 Restores Blood Flow in a Microfluidic Model of Acute Ischemic Stroke (AIS)
https://www.nature.com/articles/s42003-026-10616-y About BB-031BB-031 is an investigational RNA aptamer designed to selectively inhibit von Willebrand Factor (vWF), a central mediator of clot initiation, growth and stabilization. By targeting vWF
More news about: Basking Biosciences Inc.
Jul 30, 2026, 06:50 ET Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
helps identify patients at risk for severe chemotherapy treatment-related toxicity.Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access
More news about: Labcorp Holdings Inc
Jul 29, 2026, 09:57 ET Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
IND, and expand extrahepatic RNA delivery technologies.NANTONG, China, July 29, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and
More news about: Ractigen Therapeutics
Jul 28, 2026, 10:30 ET Biopharmaceutical Process Analytical Technology Market worth $4.32 billion by 2031 - Exclusive Report by MarketsandMarkets™
Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™
More news about: MarketsandMarkets
Jul 28, 2026, 08:30 ET Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
activating ESR1 mutations, which are associated with endocrine resistance and recurrent or metastatic estrogen receptor-positive breast cancer.RNA-sequencing analyses identified shared anti-estrogenic effects as well as distinct compound-specific transcriptional programs that may help differentiate
More news about: Atossa Therapeutics Inc
Jul 28, 2026, 08:00 ET Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026
engineers, technology innovators, and industry leaders advancing the development and manufacturing of biologics, antibodies, cell and gene therapies, RNA therapeutics, and oligonucleotide-based medicines. The conference explores the latest innovations in process development, scale-up, manufacturing, quality,
More news about: Bioprocessing Summit
Jul 28, 2026, 08:00 ET Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jul 28, 2026, 07:00 ET Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
3 severe COVID-19 clinical data showed antiviral activity when given with remdesivir, reducing mortality by 70.2% and improving median time to viral RNA clearance with no additional safety signals – with safety and tolerability demonstrated in 470 clinical trial participants," said Gilead Raday, Chief
More news about: RedHill Biopharma Ltd.
Jul 28, 2026, 00:00 ET Hepatitis D Remains an Overlooked Threat for People Living with Hepatitis B
one global analysis found progression to cirrhosis in about five years and liver cancer in about 10 years, on average. Yet access to confirmatory HDV RNA testing remains limited in many low- and middle-income countries, leaving infections undiagnosed and the true burden difficult to measure. Treatment
More news about: Huahui Health Ltd.
Jul 28, 2026, 00:00 ET Hepatitis D Remains an Overlooked Threat for People Living with Hepatitis B
one global analysis found progression to cirrhosis in about five years and liver cancer in about 10 years, on average. Yet access to confirmatory HDV RNA testing remains limited in many low- and middle-income countries, leaving infections undiagnosed and the true burden difficult to measure. Treatment
More news about: Huahui Health Ltd.
Jul 27, 2026, 09:05 ET BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. For more information, please visit
More news about: BioMarin Pharmaceutical Inc.
Jul 27, 2026, 09:00 ET Mana.bio Announces the Appointment of Laura Sepp-Lorenzino to its Scientific Advisory Board
Israel and BOSTON, July 27, 2026 /PRNewswire/ -- Mana.bio, a biotechnology company revolutionizing targeted RNA delivery through AI-enabled lipid nanoparticle (LNP) discovery and optimization, today announced the addition of renowned industry veteran, Laura Sepp-Lorenzino,
More news about: Mana.bio
Jul 27, 2026, 06:00 ET IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
Biosciences.Loss of MTAP leads to the accumulation of MTA and increased dependence on PRMT5 and MAT2A, two key enzymes involved in methylation and RNA splicing. In MTAP-deleted tumors, this biology establishes a robust synthetic lethal vulnerability that underpins the mechanistic rationale for combining
More news about: IDEAYA Biosciences, Inc.
Jul 26, 2026, 21:27 ET 晶泰科技Kodexia™：首個生成式AI+第一性原理的siRNA研發平台獲新進展，管線進入PCC確認階段
藥物的廣泛應用。針對上述行業痛點，晶泰科技構建了以 AI 為中心（AI-centric）的核酸藥物開發平台 Kodexia™，將 AI 能力貫穿於序列設計、修飾推薦、實驗驗證、遞送優化與知識產權佈局的全過程。Kodexia™ 的核心設計模塊融合了 siRNA 沉默機制、RNA 熱力學與結構特徵等第一性原理和機制知識，可針對體外活性、體內轉化、長效性、脫靶和安全性等關鍵終點分別進行訓練與協同優化，避免在單一指標上獲得局部最優，從而在兼顧藥效和安全性的同時，高效篩選出具備差異化優勢和專利自由度的候選分子。與傳統 「先設計、再逐項驗證」 的串聯流程不同，Kodexia™
More news about: 晶泰科技
Jul 23, 2026, 14:17 ET Lilac Biosciences and Soin Neuroscience Announce Publication of Clinical Review on RNA Biomarkers for Neuropathic Pain
out of the Giuliani RNA Center at Brown University, founded through close collaboration between biologists, engineers, and clinicians. Based in Providence, Rhode Island, Lilac builds next generation tools to measure RNA modifications, integrity, and quality, developing quantitative RNA workflows that enable
More news about: Soin Neuroscience
Jul 23, 2026, 13:00 ET Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
development of its Gene Writing™ and delivery platforms, with the goal of advancing in vivo genetic medicines. Our Gene Writing platform utilizes all-RNA constructs and is designed to write therapeutic messages into the genome by leveraging a process known as target-primed reverse transcription (TPRT)
More news about: Tessera Therapeutics
Jul 23, 2026, 08:32 ET Pusan National University: Beyond Antibiotics--A Paradigm Shift Toward Bacteria-Control-Centric Therapies
clinical settings," says Prof. Kim.The team identified a naturally occurring peptide called TimP, encoded by a bacterial small non-coding RNA (sRNA) RyfA, that prompts bacteria to reorganize their own outer membrane. This remodeling creates openings that allow polymyxins to penetrate the bacterial
More news about: Pusan National University
Jul 23, 2026, 07:29 ET Ribo publie des résultats positifs suite à l'essai de Phase 2a réalisé sur le vortosiran - Premières données cliniques au monde sur l'inhibition du facteur XI par pARNi après administration de plusieurs doses chez des patients atteints de coronaropathie
le traitement des maladies thromboemboliques. « Sur la base de ces résultats, nous avons lancé le programme ORBIT-XI (Optimizing RNA-Based Inhibition of Thrombosis - Optimisation de l'inhibition de la thrombose par l'ARN), qui comprend plusieurs essais de Phase 2b destinés à faciliter
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 23, 2026, 07:00 ET Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
advancing RNA-based therapeutics for neuromuscular disorders, today announced the publication of new preclinical data demonstrating central nervous system (CNS) activity of its investigational antimiR-23b therapy, ATX-01, in Myotonic Dystrophy Type 1 (DM1). ATX-01 is ARTHEx's investigational RNA therapeutic
More news about: ARTHEx Biotech
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
advancing RNA-based therapeutics for neuromuscular disorders, today announced the publication of new preclinical data demonstrating central nervous system (CNS) activity of its investigational antimiR-23b therapy, ATX-01, in Myotonic Dystrophy Type 1 (DM1). ATX-01 is ARTHEx's investigational RNA therapeutic
More news about: ARTHEx Biotech
Jul 22, 2026, 20:06 ET Ribo veröffentlicht positive Daten aus der Phase-2a-Studie zu Vortosiran - weltweit erste klinische Daten zur siRNA-vermittelten FXI-Hemmung nach wiederholter Verabreichung bei Patienten mit koronarer Herzkrankheit
FXI-Hemmung bei thromboembolischen Erkrankungen darstellt. Aufbauend auf diesen Erkenntnissen haben wir das ORBIT-XI-Programm (Optimizing RNA-Based Inhibition of Thrombosis) ins Leben gerufen, das mehrere Phase-2b-Studien umfasst, die den schnellen Übergang in die Phase-3-Entwicklung für verschiedene
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 10:11 ET Ribo revela datos positivos del ensayo de fase 2a de vortosiran
altamente diferenciado para las enfermedades tromboembólicas. Basándonos en estos hallazgos, hemos puesto en marcha el programa ORBIT-XI (Optimizing RNA-Based Inhibition of Thrombosis), que incluye varios ensayos de fase 2b diseñados para facilitar un rápido avance hacia la fase 3 de desarrollo en múltiples
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 09:00 ET Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics